Abstract

Onychomycosis affects up to 8% of the population and is most commonly caused by Trichophyton rubrum (T. rubrum) and Trichophyton mentagrophytes (T. mentagrophytes). Systemic antifungals provide higher rates of clearance compared to topical antifungals, but are associated with potentially serious side effects and drug-drug interactions. Efinaconazole, a triazole antifungal, is approved by the FDA as a 10% nail solution (Jublia®) for the treatment of distal and lateral subungual onychomycosis. Efinaconazole’s activity has been demonstrated using agar diffusion assays (ADAs) centered on cadaveric nail clippings; however, it has not been studied under real-world conditions that may provide a more accurate approximation of its true effectiveness.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.